Harpoon Therapeutics, Inc. (HARP) Financial Statements (2024 and earlier)

Company Profile

Business Address 611 GATEWAY BOULEVARD, SUITE 400
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:53,100114,600150,000155,10089,493
Cash and cash equivalents51,61444,68721,17088,73689,493
Short-term investments1,49890,411104,86059,337 
Other undisclosed cash, cash equivalents, and short-term investments(12)(20,498)23,9707,027 
Deferred costs  200600  
Other undisclosed current assets1,62722,895(20,846)(4,483)730
Total current assets:54,727137,695129,754150,61790,223
Noncurrent Assets
Operating lease, right-of-use asset10,8546,1276,5837,015
Property, plant and equipment7,2379,24810,18811,3832,998
Long-term investments and receivables  1,52223,9467,056 
Long-term investments  1,52223,9467,056 
Other noncurrent assets9118601,1215333,575
Other undisclosed noncurrent assets     5,784
Total noncurrent assets:19,00217,75741,83825,98712,357
TOTAL ASSETS:73,729155,452171,592176,604102,580
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,07320,02815,41710,0897,698
Accounts payable4,7122,6661,5722,5944,357
Accrued liabilities14,36117,36213,8457,4953,341
Deferred revenue 30,93737,46231,29911,207
Debt    1,217 
Contract with customer, liability4,250
Other undisclosed current liabilities2,4231,6491,202  
Total current liabilities:52,43359,13947,91822,51311,948
Noncurrent Liabilities
Long-term debt and lease obligation:  10,53812,31313,727 
Liabilities, other than long-term debt15,89727,70557,52246,14414,534
Deferred revenue 2,31427,70557,52246,144
Contract with customer, liability7,792
Other liabilities     6,742
Operating lease, liability13,58310,53812,31313,727
Other undisclosed noncurrent liabilities     
Total noncurrent liabilities:15,89738,24369,83559,87114,534
Total liabilities:68,33097,382117,75382,38426,482
Temporary equity, carrying amount     129,577
Equity
Equity, attributable to parent5,39958,07053,83994,220(53,479)
Common stock44331
Additional paid in capital357,921342,905221,904212,3399,111
Accumulated other comprehensive income (loss)(3)(47)341 
Accumulated deficit(352,523)(284,792)(168,071)(118,163)(62,591)
Total equity:5,39958,07053,83994,220(53,479)
TOTAL LIABILITIES AND EQUITY:73,729155,452171,592176,604102,580

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues31,91523,65417,4445,7774,750
Gross profit:31,91523,65417,4445,7774,750
Operating expenses(100,240)(140,405)(68,775)(63,983)(32,474)
Operating loss:(68,325)(116,751)(51,331)(58,206)(27,724)
Nonoperating income594301,4233,175358
Investment income, nonoperating7762401,4493,217395
Other nonoperating income (expense)(182)(210)(26)(42)(37)
Interest and debt expense     
Loss from continuing operations:(67,731)(116,721)(49,908)(55,031)(27,366)
Loss before gain (loss) on sale of properties:(116,721)(49,908)(55,031)(27,366)
Other undisclosed net loss    (541) 
Net loss:(67,731)(116,721)(49,908)(55,572)(27,366)
Other undisclosed net income attributable to parent     
Net loss available to common stockholders, diluted:(67,731)(116,721)(49,908)(55,572)(27,366)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(67,731)(116,721)(49,908)(55,572)(27,366)
Other comprehensive income (loss) 44(50)(38)41 
Other undisclosed comprehensive income     
Comprehensive loss:(67,687)(116,771)(49,946)(55,531)(27,366)
Other undisclosed comprehensive loss, net of tax, attributable to parent     
Comprehensive loss, net of tax, attributable to parent:(67,687)(116,771)(49,946)(55,531)(27,366)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: